News
NIH inventors are seeking a licensee and/or collaborator for a gene therapy to increase melanin production in patients with oculocutaneous albinism (OCA). OCA is characterized by decreased or absent pigmentation in the hair, skin, and eyes. This lack of pigmentation, caused by insufficient melanin
Axonal injury and subsequent neuronal death underpin the pathology of many neurological disorders, from acute neural injuries (motor vehicle crashes, combat-related injuries, traumatic brain injuries) to neurological diseases (multiple sclerosis, glaucoma). In the central nervous system (CNS)
Join NIH’s Steven Ferguson and Michael Salgaller for a free webinar discussing NIH’s mission to facilitate economic development beyond grant funding on April 29, 2026 at 9:30am EST. They will be discussing NIH as a premier technology transfer partner, how the process at the NIH works, and answering
Register to attend a free NIH webinar to learn about a new non-opioid small molecule for treating opioid use and substance use disorders by selectively targeting the dopamine D3 receptor. Dr. Amy Newman and her team at the National Institutes of Health’s National Institute on Drug Abuse (NIDA)